Comparing Noninvasive Ventilation Delivered Using Neurally-Adjusted Ventilatory Assist or Pressure Support in Acute Respiratory Failure

Kuruswamy Thurai Prasad, Raghava Rao Gandra, Sahajal Dhooria, Valliappan Muthu, Ashutosh Nath Aggarwal, Ritesh Agarwal, Inderpaul Singh Sehgal, Kuruswamy Thurai Prasad, Raghava Rao Gandra, Sahajal Dhooria, Valliappan Muthu, Ashutosh Nath Aggarwal, Ritesh Agarwal, Inderpaul Singh Sehgal

Abstract

Background: The use of neurally-adjusted ventilatory assist (NAVA) during noninvasive ventilation (NIV) results in better patient-ventilator interaction. Whether this improves clinical outcomes lacks dedicated study.

Methods: In this randomized controlled trial, we compared NAVA with PSV for delivering NIV in consecutive subjects with de novo acute respiratory failure. The primary outcomes were NIV failure rates and 28-d mortality. The secondary outcomes were asynchrony index, NIV-related complications, and others.

Results: We enrolled 100 subjects (50 subjects each for NAVA and PSV, 60% male) with a mean ± SD age of 56.7 ± 12 y. There was no difference in NIV failure rates (30% vs 32%, P = .83) and 28-d mortality rates (18% vs 34%, P = .07) between the NAVA and PSV arms, respectively. The median asynchrony index was significantly lower with NAVA (6.7 vs 44.8, P < .001). The use of NAVA significantly reduced NIV-related complications (32% vs 58%, P = .01). In a post hoc analysis, the use of NAVA significantly reduced the 28-d mortality in subjects with COPD exacerbation.

Conclusions: The use of NAVA during NIV did not improve NIV failure rate or 28-d mortality in subjects with acute respiratory failure. However, patient-ventilator asynchrony and NIV-related complications were reduced with NAVA.

Trial registry: www.clinicaltrials.gov (NCT03271671).

Keywords: bi-level positive airway pressure; mechanical ventilation; neurally adjusted ventilatory assist; noninvasive ventilation; pressure support ventilation; respiratory failure.

Conflict of interest statement

The authors have disclosed no conflicts of interest.

Copyright © 2021 by Daedalus Enterprises.

Source: PubMed

3
Abonnieren